Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Initial search results include only NCI-sponsored clinical trials. To search all trials, click the "REFINE SEARCH" button, scroll down to the Trial ID/Sponsor section and select the "All" check box in the Sponsor of Trial section.

View Content for:
Display:
?
Drug:  forodesine hydrochloride
Find trials that include:  Any drugs shown
Trial Status:  Closed
Results 1-11 of 11 for your search:
Start Over
Forodesine Hydrochloride (BCX-1777) for B-Cell Acute Lymphoblastic Leukemia
Phase: Phase II, Phase I
Type: Treatment
Status: Completed
Age: Any age
Sponsor: Pharmaceutical / Industry
Protocol IDs: BCX1777-Bi-04-106, NCT00289562
Phase I/II Clinical Study of Forodesine in Japanese Recurrent/Refractory Peripheral T-cell Lymphoma Patients
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Closed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: FDS-J02, NCT01776411
Phase II Study of Forodesine in Patients With Recurrent or Refractory Advanced T-Cell Leukemia
Phase: Phase II
Type: Treatment
Status: Completed
Age: Any age
Sponsor: Pharmaceutical / Industry
Protocol IDs: BIOCRYST-BCX1777-T-04-201, NCT00095381, UCLA-0404017-01
Study of Forodesine Hydrochloride in Patients With Advanced, Fludarabine-refractory Chronic Lymphocytic Leukemia (CLL)
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: BCX1777-Bo-05-204, NCT00289549
Forodesine in the Treatment of Cutaneous T-Cell Lymphoma
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: BCX1777-203, BIOCRYST-BCX1777-203, NCT00501735
Phase II Study of Forodesine in Subjects With Chronic Lymphocytic Leukemia (CLL)
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: BCX1777-210, NCT00640523
Phase I Study of BCX-1777 in Patients With Refractory Hematologic Malignancies
Phase: Phase I
Type: Treatment
Status: Closed
Age: 16 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: BIOCRYST-1777BC-102, NCT00066235
Oral Forodesine Hydrochloride (BCX-1777) in Patients With Recurrent or Refractory T/NK-cell Malignancies
Phase: Phase I
Type: Treatment
Status: Completed
Age: 20 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: BCX1777-J01, NCT00823355
Start Over